Posted by Michael Wonder on 28 Mar 2017
Roche withdraws submission for Avastin
28 March 2017 - Roche was seeking a positive CADTH recommendation for the use of bevacizumab in combination with pemetrexed and cisplatin or carboplatin (for cisplatin ineligible patients), for the first-line treatment of patients with unresectable malignant pleural mesothelioma.
Roche has requested a voluntary withdrawal of the pCODR 10100 bevacizumab (Avastin) MPM Submission. As per pCODR Procedures B3.1.6.2 b), pCODR has stopped the review.
The continuation of the review as a PAG Submission will be under consideration by the pCODR Provincial Advisory Group.
